pharma news today glp-1 obesity drug Market Overview: Agonists and the Market | Blog GLP-1 Agonists Market Report 2025-2033,

Kaufman M R, Bradley J P, Dickinson B, et al

ABSTRACT: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 RAs are common therapies for managing diabetes and obesity, but gastrointestinal (GI) adverse effects (AEs) such as nausea, vomiting, diarrhea, and constipation frequently limit therapy

PLEASE SEE OUR TERMS REGARDING YOUR RIGHTS IN ANY DISPUTE INVOLVING OUR SERVICES, INCLUDING A MANDATORY ARBITRATION CLAUSE, AND A WAIVER TO A JURY TRIAL OR CLASS ACTION, THAT LIMITS YOUR RELIEF

Lipotropics can be administered as a fat loss or weight loss tool

Patients should discuss hypoglycemia recognition and management with their prescribing physician

Contain high-risk ingredients, additives, or contaminants that may or may not be listed on the label